doi: 10.1007/978-3-7091-9113-2_53.
Effect of the new selective COMT inhibitor CGP 28014 A on the formation of 3-O-methyldopa (3OMD) in plasma of healthy subjects
Affiliations
- PMID: 2128511
- DOI: 10.1007/978-3-7091-9113-2_53
Item in Clipboard
Effect of the new selective COMT inhibitor CGP 28014 A on the formation of 3-O-methyldopa (3OMD) in plasma of healthy subjects
J Neural Transm Suppl.
1990.
Abstract
CGP 28014 A is a specific inhibitor of catechol-O-methyl transferase (COMT). The effect on COMT was assessed with the levodopa test in 5 unmedicated subjects and after pretreatment with 200-600 mg CGP 28014 p.o. Plasma concentrations of DOPA, 3-O-methyldopa (3OMD), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid were measured. CGP 28014 A decreased 3OMD not dose-related by 67% (p less than 0.05). This, and an increase of DOPAC shows COMT inhibition by this compound in humans.
Similar articles
-
Comparison of two new inhibitors of catechol O-methylation on striatal dopamine metabolism: a microdialysis study in rats.Br J Pharmacol. 1994 May;112(1):13-8. doi: 10.1111/j.1476-5381.1994.tb13021.x. Br J Pharmacol. 1994. PMID: 7518301 Free PMC article.
-
Clinical pharmacology of the new COMT inhibitor CGP 28,014.Neurochem Res. 1993 Nov;18(11):1163-7. doi: 10.1007/BF00978368. Neurochem Res. 1993. PMID: 8255368
-
CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure.Naunyn Schmiedebergs Arch Pharmacol. 1990 Sep;342(3):305-11. doi: 10.1007/BF00169442. Naunyn Schmiedebergs Arch Pharmacol. 1990. PMID: 1980718
-
Effects of the COMT inhibitor, CGP 28014, on plasma homovanillic acid and O-methylation of exogenous L-dopa in the rat.J Neural Transm Suppl. 1990;32:381-6. doi: 10.1007/978-3-7091-9113-2_52. J Neural Transm Suppl. 1990. PMID: 2128510
-
General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.Gen Pharmacol. 1994 Sep;25(5):813-24. doi: 10.1016/0306-3623(94)90082-5. Gen Pharmacol. 1994. PMID: 7835624 Review.
Cited by
-
Comparison of two new inhibitors of catechol O-methylation on striatal dopamine metabolism: a microdialysis study in rats.Br J Pharmacol. 1994 May;112(1):13-8. doi: 10.1111/j.1476-5381.1994.tb13021.x. Br J Pharmacol. 1994. PMID: 7518301 Free PMC article.
-
Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone.Naunyn Schmiedebergs Arch Pharmacol. 1992 Sep;346(3):262-6. doi: 10.1007/BF00173538. Naunyn Schmiedebergs Arch Pharmacol. 1992. PMID: 1407012
-
Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.Drugs. 2000 Jun;59(6):1233-50. doi: 10.2165/00003495-200059060-00004. Drugs. 2000. PMID: 10882160 Review.
-
Clinical pharmacology of the new COMT inhibitor CGP 28,014.Neurochem Res. 1993 Nov;18(11):1163-7. doi: 10.1007/BF00978368. Neurochem Res. 1993. PMID: 8255368
MeSH terms
Substances
LinkOut - more resources
Miscellaneous